Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2023 Mar;37(3):699-701.
doi: 10.1038/s41375-023-01809-z. Epub 2023 Jan 12.

Alternate-day dosing of pomalidomide in relapsed/ refractory multiple myeloma: a multicenter, single-arm phase 2 trial

Thilo Zander  1 , Thomas Pabst  2 , Sämi Schär  3 , Stefan Aebi  4   2 , Ulrich Mey  5 , Urban Novak  2 , Erika Lerch  6 , Gaëlle Rhyner Agocs  7 , Jeroen Goede  8 , Zuzanna Maniecka  3 , Stefanie Hayoz  3 , Axel Rüfer  9 , Christoph Renner  10 , Christoph Driessen  11
Affiliations
Clinical Trial

Alternate-day dosing of pomalidomide in relapsed/ refractory multiple myeloma: a multicenter, single-arm phase 2 trial

Thilo Zander et al. Leukemia. 2023 Mar.
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

References

    1. Miguel JS, Weisel K, Moreau P, Lacy M, Song K, Delforge M, et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013;14:1055–66. doi: 10.1016/S1470-2045(13)70380-2. - DOI - PubMed
    1. Dimopoulos MA, Palumbo A, Corradini P, Cavo M, Delforge M, Di Raimondo F, et al. Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma. Blood. 2016;128:497–503. doi: 10.1182/blood-2016-02-700872. - DOI - PMC - PubMed
    1. Moreau P, Dimopoulos MA, Richardson PG, Siegel DS, Cavo M, Corradini P, et al. Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: a pooled analysis. Eur J Haematol. 2017;99:199–206. doi: 10.1111/ejh.12903. - DOI - PubMed
    1. Richardson PG, Oriol A, Beksac M, Liberati AM, Galli M, Schjesvold F, et al. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20:781–94. doi: 10.1016/S1470-2045(19)30152-4. - DOI - PubMed
    1. Attal M, Richardson PG, Rajkumar SV, San-Miguel J, Beksac M, Spicka I, et al. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Lancet (Lond, Engl) 2019;394:2096–107. doi: 10.1016/S0140-6736(19)32556-5. - DOI - PubMed

Publication types